Sep 20, 2022 | Ad-hoc, Featured news, Finance, News
Two contracts signed with order volumes of CHF 25 million in 2023 and CHF 150 million in 2024. Potential for significantly larger orders for the following years under negotiation. Companies agree to maintain customer confidentiality. Bachem Group (SIX: BANB) today...
Aug 25, 2022 | Ad-hoc, Featured news, Finance, News
Group sales at CHF CHF 234.9 million at half year (-1.8% compared to prior-year period). EBITDA of CHF 67.3 million (-10.8% compared to prior-year period) with a margin of 28.7%. EBIT of CHF 51.6 million (-16.8% compared to prior-year period) with a margin of 22.0%....
Apr 26, 2022 | Ad-hoc, CMC development, Featured news, News, Oligonucleotides
Strategic collaboration with Lilly to develop innovative and efficient processing solutions for the manufacture of oligonucleotide-based drug substances. The annual order volume has the potential to achieve around CHF 100 million, depending on Bachem reaching...
Mar 18, 2022 | Ad-hoc, Featured news, Finance, News
Group sales increase to CHF 503.2 million, up 25.2% year-on-year. EBITDA increases from CHF 122.6 million to CHF 157.4 million with a margin of 31.3%. Operating income EBIT increases from CHF 96.7 million to CHF 128.9 million with a margin of 25.6%. Net income...
Jan 6, 2022 | Ad-hoc, Featured news, Leadership, News, Press
Changes to the Bachem Corporate Executive Committee and strengthening of the organization in North America Torsten Wöhr to join the CEC as Chief Marketing Officer (CMO) Anne-Kathrin Stoller to take on a new role as Chief Operating Officer Bachem Americas, reporting...
Oct 19, 2021 | Ad-hoc, Featured news, Finance, News, Press
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Bachem raises CHF...
